About Trius Therapeutics (NASDAQ:TSRX)
Trius Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of antibiotics for life threatening infections. The Company is developing torezolid phosphate, an intraveneous (IV) and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections (ABSSSI), and subsequently for other indications. In addition, the Company is developing antibiotics for gram-negative infections using its discovery platform under two contracts: one funded by the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH) and the other funded by the Defense Threat Reduction Agency (DTRA), a part of the Department of Defense. In September 2013, Cubist Pharmaceuticals Inc announced that it has completed the acquisition of Trius Therapeutics Inc.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
EPS (Most Recent Fiscal Year)N/A
Return on EquityN/A
Return on AssetsN/A
Trius Therapeutics (NASDAQ:TSRX) Frequently Asked Questions
What is Trius Therapeutics' stock symbol?
Trius Therapeutics trades on the NASDAQ under the ticker symbol "TSRX."
Has Trius Therapeutics been receiving favorable news coverage?
News coverage about TSRX stock has trended positive this week, according to Accern. The research group identifies negative and positive media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Trius Therapeutics earned a news sentiment score of 0.42 on Accern's scale. They also assigned media stories about the biopharmaceutical company an impact score of 43.95 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future.
How do I buy shares of Trius Therapeutics?
Shares of TSRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How can I contact Trius Therapeutics?
Trius Therapeutics' mailing address is 65 Hayden Ave, LEXINGTON, MA 02421-7994, United States. The biopharmaceutical company can be reached via phone at +1-781-8608660.
MarketBeat Community Rating for Trius Therapeutics (TSRX)MarketBeat's community ratings are surveys of what our community members think about Trius Therapeutics and other stocks. Vote "Outperform" if you believe TSRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TSRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Trius Therapeutics (NASDAQ:TSRX) Analyst Ratings History
(Data available from 4/25/2016 forward)
|Date||Brokerage||Action||Rating||Price Target||Impact on Share Price||Details|
Trius Therapeutics (NASDAQ:TSRX) Earnings History and Estimates Chart
Trius Therapeutics (NASDAQ TSRX) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/6/2013||Q212||($0.33)||($0.41)||$3.71 million||$1.30 million||View||N/A|
|5/7/2013||Q1 2013||($0.33)||($0.34)||$6.31 million||$1.73 million||View||N/A|
Trius Therapeutics (NASDAQ:TSRX) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Trius Therapeutics (NASDAQ TSRX) Insider Trading and Institutional Ownership History
Trius Therapeutics (NASDAQ TSRX) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|7/22/2013||John Finn||Insider||Sell||1,000||$12.10||$12,100.00|| |
|7/15/2013||John Finn||Insider||Sell||3,500||$10.55||$36,925.00|| |
|7/12/2013||John Finn||Insider||Sell||6,500||$9.81||$63,765.00|| |
|7/11/2013||Michael Morneau||CAO||Sell||20,000||$9.75||$195,000.00|| |
|7/1/2013||Philippe Prokocimer||Insider||Sell||2,000||$8.14||$16,280.00|| |
|6/12/2013||John Finn||Insider||Sell||3,000||$9.08||$27,240.00|| |
|6/11/2013||John Finn||Insider||Sell||1,000||$8.94||$8,940.00|| |
|6/4/2013||Ken Bartizal||Insider||Sell||2,000||$7.90||$15,800.00|| |
|6/3/2013||Philippe Prokocimer||Insider||Sell||2,000||$7.75||$15,500.00|| |
|5/24/2013||Philippe Prokocimer||Insider||Sell||12,000||$7.93||$95,160.00|| |
|5/14/2013||Ken Bartizal||Insider||Sell||12,000||$7.85||$94,200.00|| |
|5/14/2013||Michael Morneau||CAO||Sell||20,000||$7.75||$155,000.00|| |
|5/13/2013||Philippe Prokocimer||Insider||Sell||12,000||$7.65||$91,800.00|| |
|5/10/2013||John Finn||Insider||Sell||3,000||$7.48||$22,440.00|| |
Trius Therapeutics (NASDAQ TSRX) News Headlines
Trius Therapeutics (NASDAQ:TSRX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Trius Therapeutics (NASDAQ:TSRX) Income Statement, Balance Sheet and Cash Flow Statement
Trius Therapeutics (NASDAQ TSRX) Stock Chart for Wednesday, April, 25, 2018